DLL3
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NYJ7-1 |
---|---|
Species | Human |
Sequence | Val311-Ala479 |
Purity | > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
Endotoxin Level | Less than 1EU per µg by the LAL method. |
Biological Activity | Immobilized DLL3 Domain (311-479)[Biotin], His&Avi, Human (Cat.No.: Z03953) at 0.5 µg/ml (100 µl/Well) on streptavidin precoated plate can bind Anti-DLL3 Antibody, hFc Tag |
Expression System | HEK293 |
Theoretical Molecular Weight | 21.20 kDa |
Formulation | Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4). |
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 µg/ml. |
Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background | Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors. |
---|

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.